Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | ME2 | P23368 | 1/20 | 0.43 |
| ▸ | ME1 | P48163 | 1/20 | 0.43 |
| ▸ | ME3 | Q16798 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26330809 | 0.84 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL26331458 | 0.83 | L3MBTL1 (0.63) | ALDH1A1KMT2ASMN1; SMN2POLBLMNA | |
| SCHEMBL22874751 | 0.81 | SMN1; SMN2 (0.58) | ALDH1A1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL26330812 | 0.80 | HSD11B1 (0.52) | ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL22874890 | 0.77 | SMN1; SMN2 (0.54) | ALDH1A1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL26330807 | 0.77 | GRIN2B (0.51) | SMN1; SMN2GRIN2BLMNACYP2C19 | |
| SCHEMBL20386535 | 0.74 | SMN1; SMN2 (0.59) | ALDH1A1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL14293643 | 0.74 | SMN1; SMN2 (0.50) | ALDH1A1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL11361784 | 0.73 | NPC1 (0.50) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL11475781 | 0.73 | MGLL (0.41) | ALDH1A1MEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286982-A1 | PROTEASOME ENHANCERS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286982-A1 | PROTEASOME ENHANCERS AND USES THEREOF | PSME3, PSME1, PSME4 | ALDH1A1 3557/4885MEN1 4293/4885KMT2A 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.